<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03774238</url>
  </required_header>
  <id_info>
    <org_study_id>UF7699</org_study_id>
    <nct_id>NCT03774238</nct_id>
  </id_info>
  <brief_title>Determinants of the Vascular Response to Training in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <acronym>cDysEndoBPCO</acronym>
  <official_title>Biological and Functional Determinants of the Endothelial and Vascular Response to Exercise Training in COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular comorbidities constitute a major burden in COPD patients. The atherosclerosis&#xD;
      process is preceded by the onset of an endothelial dysfunction (assessed by the flow-mediated&#xD;
      dilatation (FMD)), which is a risk factor for later ischemic vascular complications and&#xD;
      death. In COPD, this endothelial dysfunction could be explained by intrinsic endothelial cell&#xD;
      properties, or the effect of a pathogenic endothelial cell microenvironment (inflammation&#xD;
      and/or oxidative stress). Exercise training constitue a powerful stimulus for the endothelial&#xD;
      function, and could be mediated by the mobiliaztion and function of endothelial progenitors.&#xD;
      While exercise training is an efficient intervention in COPD patients, its vascular effect&#xD;
      appear blunted. The endothelial function response to training has appeared heterogeneous in&#xD;
      COPD patients, and possibly linked to the endothelial cel lesion. Thus, endothelial function&#xD;
      (assessed by the FMD) response to exercise training would be lower in COPD patients with a&#xD;
      baseline impairment of the their FMD. In addition, of biological and functional factors could&#xD;
      explained the magnitude of the FMD response in COPD patients.The aim of the study are thus :&#xD;
&#xD;
      To compare the FMD change in COPD patients with FMD above (FMD+) and under the median FMD&#xD;
      (FMD-) after 4 weeks of exercise training in the whole study population.&#xD;
&#xD;
      To compare between COPD patients FMD+, COPD patients FMD- and healthy &quot;control&quot; subjects, the&#xD;
      endothelial inflammation and senescence at baseline and the endothelial progenitor&#xD;
      mobilization and function change induced by exercise (maximal exercise test and training).&#xD;
&#xD;
      To compare between COPD patients FMD+, COPD patients FMD- and healthy &quot;control&quot; subjects the&#xD;
      effect of the endothelial microenvironment on the cellular pathways regulating the&#xD;
      endothelial function in vitro at baseline and changes after exercise training.&#xD;
&#xD;
      To test in COPD patients the association between the magnitude of the FMD changes after&#xD;
      training and biological, functional and clinical factors (inflammation oxidative stress&#xD;
      markers, endothelial biomarkers, pulmonary impairment and phenotype, cardiovascular risks&#xD;
      factors, vascular function, metabolic markers, physical activity level, …)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>COPD patient group (n=50) and Healthy control Group (n=24)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of Flow-Mediated Dilatation (FMD)</measure>
    <time_frame>post exercise and after 4 +/- 2 weeks of training</time_frame>
    <description>Measure of FMD by EndoPAT2000©</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of biological vascular markers</measure>
    <time_frame>after 4 +/- 2 weeks of training</time_frame>
    <description>E-selectin soluble (sE-sel), endotheline 1 (ET1), facteur von Willebrand (vWF), vascular endothelial growth factor A (VEGF-A), Fms-like tyrosine kinase receptor 1 soluble (sFlt-1), Angiopoietine 1 et 2 (Ang-1 Ang-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of colonies and function of Endothelial-Colony Formaing cells (ECFC) in vitro</measure>
    <time_frame>post exercise and after 4 +/- 2 weeks of training</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number endothelial progenitors</measure>
    <time_frame>post exercise and after 4 +/- 2 weeks of training</time_frame>
    <description>CD34+, CD45+ and KDR + subpopulations by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular function parameters</measure>
    <time_frame>after 4 +/- 2 weeks of training</time_frame>
    <description>Systolic pressure index (in AU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular function parameters</measure>
    <time_frame>after 4 +/- 2 weeks of training</time_frame>
    <description>Intima-media thickness (in mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular function parameters</measure>
    <time_frame>after 4 +/- 2 weeks of training</time_frame>
    <description>Pulse-wave velocity (in ms-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse-wave velocity (in ms-1)</measure>
    <time_frame>after 4 +/- 2 weeks of training</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of systemic inflammation</measure>
    <time_frame>after 4 +/- 2 weeks of training</time_frame>
    <description>C-Reactive protein (in ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of oxidative stress</measure>
    <time_frame>after 4 +/- 2 weeks of training</time_frame>
    <description>Lipid peroxidation (in micromol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function parameters</measure>
    <time_frame>after 4 +/- 2 weeks of training</time_frame>
    <description>Maximum isometric voluntary contraction (in N.m)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity and vascular adaptation parameters</measure>
    <time_frame>after 4 +/- 2 weeks of training</time_frame>
    <description>Maximal oxygen uptake (VO2max, in mL/kg/min)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>COPD Patients</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>COPD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMD analysis Endothelial progenitors Exercise test Exercise training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMD analysis Endothelial progenitors Exercise test</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FMD analysis</intervention_name>
    <description>Blood sample and vascular exploration.</description>
    <arm_group_label>COPD patients</arm_group_label>
    <arm_group_label>Healthy subject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A/ COPD patients&#xD;
&#xD;
          -  age between 35 and 85 years old&#xD;
&#xD;
          -  spirometry showing an FEV1/VC &lt; lower limit of normal&#xD;
&#xD;
          -  with an indication for a pulmonary rehabilitation program&#xD;
&#xD;
          -  written and informed consent for this study signed by the patient&#xD;
&#xD;
        B/ Healthy subjects&#xD;
&#xD;
          -  age between 35 and 85 years old&#xD;
&#xD;
          -  no cardiovascular or respiratory disease&#xD;
&#xD;
          -  normal spirometry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstabilized comorbidity&#xD;
&#xD;
          -  Subject in a period of exclusion relative to another protocol&#xD;
&#xD;
          -  Major protected by law&#xD;
&#xD;
          -  Subject participating in another research protocol&#xD;
&#xD;
          -  Subject not affiliated to a social security scheme&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Patient deprived of freedom by court or administrative order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fares Gouzi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fares Gouzi, MD, PhD</last_name>
    <phone>+33467335908</phone>
    <email>f-gouzi@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montpellier and Nimes University Hospitals</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fares Gouzi, MD, PhD</last_name>
      <phone>+33 4 67 33 59 08</phone>
      <email>f-gouzi@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital, Paris</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flow-mediated dilatation</keyword>
  <keyword>COPD</keyword>
  <keyword>Pulmonary Rehabilitation</keyword>
  <keyword>Comorbidities</keyword>
  <keyword>endothelial cell</keyword>
  <keyword>oxidative stress</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

